SOLUBLE AND ANTIGENIC PHOSPHOINOSITIDE PHOSPHATES

描述(改编自应用)：磷脂酰肌醇多磷酸(PtdInsPns，或简称PIPns)是由磷酸酶和激酶相互作用合成的，是细胞通讯中的关键信号分子。申请人已经合成并向世界各地的研究人员提供了具有生物学意义的PIPns衍生物的“配对集合”，从而实现了其第一级战略。在第一阶段，我们优化了含有四个二酰基的PIPns的合成和表征：(I)短链胶束形成类似物，(Ii)中间链两亲性(或水溶性)类似物，(Iii)长链胶束形成类似物，和(Iv)带有报告基团的氨基功能化链。在第二阶段，我们建议制备试剂，用于在生化和细胞研究中检测PIPns的变化，并用于药物和靶标发现工作。首先，申请者将扩展其产品线，加入两个系列的酰基修饰的荧光PIPns，BODIPY和NBD系列，以研究脂质依赖的信号通路。其次，申请者将使用酰基功能化的PIPns来制备抗原型的PIPns，我们将使用这些抗原型来制备PIPn特异性的单抗。第三，申请人将开发固定化氨基糖苷柱，用于定量分析和纯化天然合成和化学修饰的PIPns。建议的商业应用：1。销售用于基础研究的试剂本身。2.销售用于基础研究的抗体本身。3.药物发现，忘记新的拮抗剂和酶抑制剂的发现。

DESCRIPTION (Adapted from the application): Phosphoinositide polyphosphates (PtdInsPns, or simply PIPns) biosynthesized by the interplay of phosphatases and kinases, are key signaling molecules in cellular communication. The applicant has synthesized and provided "matched sets" of PIPns derivatives of biological interest to researchers worldwide thereby achieving its first tier strategy. During Phase I, we optimized synthesis and characterization of PIPns with four diacyl moieties: (i) short-chain micelle-forming analogs, (ii) intermediate chain amphipathic (or water-soluble) analogs, (iii) long-chain micelle-forming analogs, and (iv) amino-functionalized chains with reporter groups attached. In Phase II, we propose to prepare reagents for the detection of changes in PIPns in biochemical and cellular studies and for use in drug and target discovery efforts. First, the applicant will expand its product line with the incorporation of two series of acyl-modified fluorescent PIPns, the BODIPY and NBD series, to study lipid-dependent signaling pathways. Second, the applicant will employ acyl-functionalized PIPns to prepare antigenic forms of the PIPns and we will use these to prepare PIPn-specific monoclonal antibodies. Third, the applicant will develop immobilized- aminoglycoside columns for the quantitative analysis and purification of naturally occurring synthetic, and chemically modified PIPns. PROPOSED COMMERCIAL APPLICATION: 1. Sale of reagents themselves for basic research. 2. Sales of antibodies themselves for basic research. 3. Drug discovery and forget discovery for new antagonist and enzyme inhibitors.